Glaukos (GKOS) to Release Earnings on Wednesday

Glaukos (NYSE:GKOS) is scheduled to announce its earnings results after the market closes on Wednesday, July 31st. Analysts expect the company to announce earnings of ($0.51) per share for the quarter. Glaukos has set its FY 2024 guidance at EPS.Investors interested in registering for the company’s conference call can do so using this link.

Glaukos (NYSE:GKOS) last announced its quarterly earnings data on Wednesday, May 1st. The medical instruments supplier reported ($0.70) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.12). The company had revenue of $85.60 million for the quarter, compared to analysts’ expectations of $79.60 million. Glaukos had a negative return on equity of 24.69% and a negative net margin of 43.15%. The company’s revenue was up 15.8% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.59) earnings per share. On average, analysts expect Glaukos to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Glaukos Stock Performance

NYSE:GKOS opened at $119.69 on Tuesday. Glaukos has a fifty-two week low of $59.22 and a fifty-two week high of $126.96. The firm’s 50 day moving average is $116.09 and its two-hundred day moving average is $102.31. The company has a market cap of $6.03 billion, a P/E ratio of -41.56 and a beta of 1.06. The company has a quick ratio of 4.68, a current ratio of 5.38 and a debt-to-equity ratio of 0.78.

Insider Activity at Glaukos

In other Glaukos news, CFO Alex R. Thurman sold 442 shares of the company’s stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $105.69, for a total value of $46,714.98. Following the transaction, the chief financial officer now directly owns 52,090 shares of the company’s stock, valued at approximately $5,505,392.10. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, CFO Alex R. Thurman sold 442 shares of Glaukos stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $105.69, for a total value of $46,714.98. Following the completion of the transaction, the chief financial officer now directly owns 52,090 shares in the company, valued at $5,505,392.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Joseph E. Gilliam sold 2,250 shares of the company’s stock in a transaction that occurred on Friday, July 5th. The shares were sold at an average price of $121.39, for a total value of $273,127.50. Following the sale, the chief operating officer now owns 101,845 shares in the company, valued at approximately $12,362,964.55. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 21,444 shares of company stock valued at $2,411,171. Insiders own 6.40% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on GKOS shares. Jefferies Financial Group upgraded Glaukos from a “hold” rating to a “buy” rating and raised their price objective for the stock from $84.00 to $125.00 in a report on Monday, May 6th. JPMorgan Chase & Co. boosted their price objective on shares of Glaukos from $108.00 to $110.00 and gave the stock an “overweight” rating in a research note on Thursday, May 2nd. BTIG Research raised their target price on shares of Glaukos from $112.00 to $131.00 and gave the company a “buy” rating in a research note on Monday, July 15th. Wells Fargo & Company lifted their target price on shares of Glaukos from $110.00 to $120.00 and gave the company an “overweight” rating in a report on Monday, June 3rd. Finally, Citigroup downgraded Glaukos from a “buy” rating to a “neutral” rating and increased their price target for the company from $130.00 to $132.00 in a report on Wednesday, July 10th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Glaukos currently has an average rating of “Moderate Buy” and a consensus price target of $120.64.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.